Boston Scientific
Open
$56.64
Prev. Close
$56.64
High
$56.64
Low
$56.56
Market Snapshot
$84.72B
29.2
1.26
$16.75B
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Boston Scientific's shares dropped 17.6% due to disappointing electrophysiology results and a securities fraud lawsuit, while Johnson & Johnson raised valuation concerns in a pending trial.
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Recently from Cashu

Boston Scientific's FDA Clearance and €75 Million R&D Investment Enhance Urology Innovations
Boston Scientific Corporation achieves a significant milestone with the FDA's 510(k) clearance of the Asurys Fluid Management System, marking an important advancement in its urology technology portfol…
Boston Scientific's WATCHMAN FLX: A Game-Changer for Stroke Prevention in Atrial Fibrillation
Transformative Stroke Prevention in Atrial Fibrillation: Boston Scientific's WATCHMAN FLX Revolutionizes Treatment Options Boston Scientific is making headlines with its innovative WATCHMAN FLX device…
Boston Scientific Hit by Class Action Lawsuit Alleging Securities Fraud and Misleading Investors
Boston Scientific Faces Class Action Lawsuit Over Alleged Securities Fraud In recent developments, Boston Scientific Corporation finds itself in the midst of a class action lawsuit related to allegati…
Boston Scientific Faces Lawsuit Over Alleged Misleading Growth Claims in Electrophysiology Division
Boston Scientific Faces Legal Challenges Over Electrophysiology Growth Claims Boston Scientific Corporation is currently embroiled in a class action lawsuit over allegations of securities fraud relate…